AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca ...Middle East

ROCKVILLE, Md. and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to...

Hence then, the article about abelzeta announces remaining china rights to gpc3 armored car t therapy to be acquired by astrazeneca was published today ( Monday 19/01/2026 - 03:43 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca )

Also on site :

• Finn Wolfhard's 'Stranger Things' SNL Skit Met With Backlash From Fans
• Who Is Katie Bates’ Husband Travis Clark? What We Know About the Affair Admission
• Trump announces new tariffs over Greenland: How have EU allies responded?